Rab Diagnostics

Description

Rab Diagnostics develops biomarker tools, assays and the RabCANCER platform to predict antibody–drug conjugate response for pharma companies, clinical trials and diagnostic kit development in oncology.

Rab Diagnostics is located in the Oslo ecosystem.

Related

• ThelperThelper develops antiviral antibody–drug conjugates that target a virally encoded biomarker abundantly expressed in aggressive, metastatic…
• ScientaLabScientaLab develops a foundation model that predicts human immune response in immunology and inflammation, using multi-disease,…
• Orakl OncologyOrakl Oncology builds an AIxBio engine that analyzes multimodal patient data and living biological samples to predict drug responses,…
• XENOTHERAXENOTHERA develops glyco humanized antibody technology for immunological treatments, lists pipeline products and clinical trials for…
• RS ResearchRS Research develops targeted oncology therapies and smart nanomedicines using the Sagitta® polymer-drug conjugate platform for targeted…
• EnzyTagEnzyTag develops peptiligase-based synthetic routes for manufacturing peptide new chemical entities, small proteins, and peptide…
• OncomatryxOncomatryx targets the tumor microenvironment with stroma-focused antibody-drug conjugates, applying this approach to metastatic solid…
• TubulisTubulis generates antibody–drug conjugates and administers them with a proprietary platform that yields uniquely matched ADCs having…
• BioInvent InternationalBioInvent International discovers and develops antibody therapeutics for cancer treatment, using immunology, cancer biology, antibody…